Journal Homepage: www.ijarpr.com ISSN: 3049-0103 (Online)

International Journal of Advance Research Publication and Reviews

Vol 03, Issue 10, pp 367-371, October, 2026

# Comprehensive Review: The Role of Natural and Synthetic Aphrodisiacs in Managing Infertility and Sexual Dysfunction

***Binny Binoy[1], Dr. Abdul Vahab[2], Dr. Jyoti Harindran[3]***

***[1]M Pharm Pharmacology Student, [2]Professor, [3]Principal***

***Department of Pharmaceutical Sciences, Department of Pharmaceutical Sciences Rd, Cheruvandoor, Ettumanoor, Kerala 686631***

**ABSTRACT**

Infertility and sexual dysfunction represent significant global health challenges affecting an estimated 10–15% of couples worldwide. Reproductive dysfunction encompasses male etiologies (such as erectile dysfunction, oligospermia, and asthenospermia) and female etiologies (including hypoactive sexual desire disorder, ovulatory dysfunctions, and endocrine pathologies). Aphrodisiacs categorized into natural phytotherapeutics and synthetic pharmacological agents play a major role in restoring reproductive capacity and sexual performance. Standard pharmaceutical options such as Sildenafil citrate, Tadalafil, Clomiphene citrate, and Cabergoline act via targeted biochemical mechanisms including phosphodiesterase type 5 (PDE5) inhibition, gonadotropin stimulation, and dopamine receptor agonism. Conversely, natural botanical aphrodisiacs like *Tribulus terrestris*, *Panax ginseng*, *Lepidium meyenii* (Maca), *Withania somnifera*, and *Eurycoma longifolia* modulate hypothalamic-pituitary-gonadal (HPG) axis signaling, enhance nitric oxide bioavailability, and mitigate cellular oxidative stress. This review provides a rigorous comparative synthesis of both synthetic and botanical aphrodisiacs, detailing their mechanisms of action, clinical evidence, side-effect profiles, drug interactions, and potential integration into contemporary reproductive medicine.

**Keywords:** Aphrodisiacs, Sildenafil Citrate, Infertility, Erectile Dysfunction, Spermatogenesis, Phytotherapy, Nitric Oxide, HPG Axis

## 1. Introduction

Infertility is defined by the World Health Organization (WHO) as a failure to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse [1]. The underlying pathology involves complex, interdependent interactions between physiological, psychological, and neuroendocrine systems. Impairments in libido, erectile mechanics, ejaculatory function, or oocyte quality directly reduce fecundity rates in clinical populations [2].

Modern medicine addresses reproductive failure using both synthetic pharmaceuticals and botanical products. Synthetic agents are engineered for high receptor specificity and predictable pharmacokinetics, primarily targeting peripheral vascular tone or central endocrine pathways [3]. Natural aphrodisiacs offer multi-targeted therapeutic properties combining antioxidant, adaptogenic, and hormone-modulating effects [4]. Understanding the synergy, individual efficacy, and potential risks associated with both natural and synthetic aphrodisiacs is essential for optimized patient-centric fertility treatments.

## 2. Physiological Classification and Biochemical Pathways

Aphrodisiac agents are systematically categorized based on their therapeutic origin into synthetic pharmaceuticals and botanical remedies, as well as their primary site of action into central and peripheral pathways. Central aphrodisiacs act directly on the central nervous system to enhance sexual drive, whereas peripheral aphrodisiacs modulate vascular tone, endothelial signaling, or gonadal steroidogenesis [5].

### *2.1. The Nitric Oxide (NO) / Cyclic GMP Cascade*

Sexual stimulation induces the local enzymatic release of Nitric Oxide (NO) from non-adrenergic, non-cholinergic (NANC) nerves and vascular endothelial cells. NO diffuses into surrounding smooth muscle cells, activating soluble guanylyl cyclase (sGC) to convert guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Accumulated intracellular cGMP causes rapid smooth muscle relaxation, arterial vasodilation, and subsequent penile erection or clitoral and vaginal engorgement [6]. Phosphodiesterase type 5 (PDE5) breaks down cGMP back into inactive 5'-GMP,

returning smooth muscle tone to baseline.

### *2.2. The Hypothalamic-Pituitary-Gonadal (HPG) Axis*

Central regulation of reproductive physiology is governed by pulsed Gonadotropin-Releasing Hormone (GnRH) release from the hypothalamus. GnRH prompts the anterior pituitary gland to secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). LH binds to testicular Leydig cells to induce testosterone biosynthesis, while FSH acts on Sertoli cells to sustain spermatogenesis. Central dopamine acts as a primary facilitator of GnRH and pro-sexual behavior, whereas elevated prolactin and serotonin exert strong inhibitory influences [7].

## 3. Standard Synthetic Pharmacological Aphrodisiacs

### *3.1. Sildenafil Citrate and Tadalafil (PDE5 Inhibitors)*

Sildenafil citrate and Tadalafil represent the gold standard for treating erectile dysfunction by selectively inhibiting the PDE5 enzyme, thereby preventing cGMP degradation in the corpus cavernosum. This maintains vascular smooth muscle relaxation and optimizes erectile response to endogenous NO release [8]. While PDE5 inhibitors do not directly alter hormonal spermatogenesis, they effectively treat severe erectile failure, enabling natural coitus and insemination. Furthermore, clinical trials indicate that systemic or intravaginal Sildenafil administration improves uterine artery blood flow and endometrial thickness during assisted reproduction cycles [9]. Common adverse effects include headache, facial flushing, dyspepsia, nasal congestion, and transient visual disturbances. Concurrent administration with organic nitrates is strictly contraindicated due to the risk of severe, fatal hypotension [10].

### *3.2. Clomiphene Citrate (Selective Estrogen Receptor Modulator)*

Clomiphene citrate functions by blocking estrogen receptors at the level of the hypothalamus and pituitary gland. By preventing negative feedback signaling from endogenous estrogen, Clomiphene stimulates continuous hypothalamic GnRH release, which in turn elevates pituitary LH and FSH secretion [11]. It is widely prescribed off-label for idiopathic male infertility and hypogonadotropic hypogonadism to elevate endogenous testosterone levels and improve both sperm concentration and motility [12].

### *3.3. Cabergoline (Dopamine D2 Receptor Agonist)*

Cabergoline is a potent, long-acting dopamine D2 receptor agonist that selectively suppresses pituitary prolactin secretion [13]. Hyperprolactinemia suppresses central GnRH release, leading to hypogonadism, erectile failure, lost libido, and anovulation. By normalizing serum prolactin levels, Cabergoline restores sexual desire, erectile capability, and regular ovulatory cycles in affected patients [14].

### *3.4. Bremelanotide (Melanocortin Receptor Agonist)*

Bremelanotide is a synthetic peptide agonist that targets central melanocortin receptors (MC3R and MC4R) within the central nervous system. Indicated primarily for hypoactive sexual desire disorder (HSDD) in premenopausal women, Bremelanotide bypasses peripheral vascular mechanics to enhance central sexual desire and arousal directly [15].

## 4. Detailed Pharmacological Profile of Botanical Aphrodisiacs

### *4.1. Tribulus terrestris*

The primary active phytoconstituents of *Tribulus terrestris* are protodioscin and furostanol saponins belonging to the Zygophyllaceae family. Protodioscin undergoes biotransformation to dehydroepiandrosterone (DHEA), which stimulates pituitary LH release and promotes testicular Leydig cell steroidogenesis [16]. In clinical trials involving oligospermic patients, *Tribulus terrestris* extract significantly increases total sperm concentration, progressive motility, and overall erectile hardness scores [17]. The primary side effect is limited to mild, transient gastrointestinal discomfort.

### *4.2. Panax ginseng*

*Panax ginseng* contains bioactive ginsenosides (such as Rg1 and Rb1) as its principal active compounds. Ginsenosides upregulate endothelial nitric oxide synthase (eNOS) gene expression, facilitating direct NO release and protecting germinal epithelial cells from oxidative damage [18]. Clinical data confirm that *Panax ginseng* administration leads to measurable improvements in penile rigidity, intercourse satisfaction, and sperm mitochondrial activity [19]. High therapeutic doses can occasionally cause mild insomnia or slight elevations in blood pressure.

### *4.3. Lepidium meyenii (Maca)*

Native to the Andean region, *Lepidium meyenii* contains macamide, macaene, and glucosinolate compounds. Maca enhances sexual desire and seminal parameters through non-hormonal pathways by providing direct energy substrates to Leydig cells and supporting germ cell proliferation [20]. Clinical

evaluations show that Maca significantly increases total seminal volume, sperm count per ejaculation, and sperm motility without altering circulating serum testosterone, LH, or FSH levels [21].

### *4.4. Withania somnifera (Ashwagandha)*

*Withania somnifera* is rich in steroidal lactones known as withanolides and sitoindosides. Its powerful adaptogenic activity lowers elevated serum cortisol levels, replenishes seminal plasma enzymatic antioxidants (such as superoxide dismutase and catalase), and preserves sperm DNA integrity [22]. In clinical trials of infertile men, 90-day supplementation resulted in a 167% increase in sperm concentration, a 53% increase in semen volume, and a marked reduction in sperm DNA fragmentation [23]. Mild drowsiness or gastric upset are occasionally reported.

### *4.5. Eurycoma longifolia (Tongkat Ali)*

*Eurycoma longifolia* contains bioactive quassinoids, particularly eurycomanone. Eurycomanone inhibits the aromatase enzyme—preventing the peripheral conversion of testosterone into estrogen—and displaces bound testosterone from Sex Hormone-Binding Globulin (SHBG) [24]. Clinical trials demonstrate significant increases in bioavailable free testosterone levels, improved sperm morphology, and higher pregnancy outcomes in couples dealing with idiopathic male factor infertility [25].

## 5. Comparative Evaluation of Synthetic and Botanical Agents

When comparing synthetic pharmaceuticals directly with botanical aphrodisiacs, distinct operational differences emerge across their clinical indications, mechanisms, and risk profiles.

Synthetic agents like Sildenafil citrate and Tadalafil offer rapid, highly predictable efficacy for peripheral vascular conditions like erectile dysfunction, but they carry potential cardiovascular risks including severe hypotension when mixed with nitrates, along with common side effects like headaches and flushing. Synthetic hormonal modulators like Clomiphene citrate selectively target central estrogen receptors to restore LH and FSH secretion, though they can cause visual disturbances and mood alterations. Cabergoline specifically reverses hyperprolactinemic infertility by suppressing pituitary prolactin, though it may cause orthostatic dizziness and nausea [8, 11, 13].

In contrast, botanical agents act through broader, multi-targeted pathways. *Tribulus terrestris* relies on saponin-mediated DHEA conversion to stimulate LH and boost sperm concentration, exhibiting minimal adverse effects beyond occasional mild gastric upset. *Panax ginseng* enhances eNOS activity to generate NO for vascular support while simultaneously offering antioxidant protection to germ cells, with high doses occasionally causing insomnia. *Withania somnifera* prioritizes systemic cortisol reduction and reactive oxygen species (ROS) scavenging to prevent sperm DNA fragmentation, presenting a very favorable safety profile. *Lepidium meyenii* improves semen volume and libido via non-hormonal metabolic support, avoiding systemic endocrine disruption entirely [16, 18, 20, 22].

## 6. Safety, Adulteration, and Drug Interactions

Integrating synthetic pharmaceuticals and botanical aphrodisiacs into clinical protocols introduces important safety considerations:

- **Herb-Drug Interactions:** Botanical products with potent vasodilatory effects (such as *Panax ginseng*) can dangerously potentiate the hypotensive action of synthetic PDE5 inhibitors like Sildenafil, predisposing patients to sudden blood pressure drops [26].
- **Supplement Adulteration:** Unregulated over-the-counter herbal enhancement products are frequently adulterated with unlisted synthetic PDE5 inhibitors or undeclared structural analogs, creating life-threatening risks for patients taking prescription nitrate medications [27].
- **Extract Standardization:** Botanical extracts exhibit batch-to-batch variation based on soil chemistry, harvest timing, and extraction methodologies, which complicates precise dosage standardization in clinical practice [28].

## 7. Discussion

Managing infertility through aphrodisiac therapy requires addressing both acute vascular mechanics and underlying cellular pathologies. Synthetic drugs such as Sildenafil citrate and Tadalafil provide rapid, reliable restoration of erectile function, while endocrine agents like Clomiphene effectively restore gonadotropin drives. However, synthetic therapies generally do not address oxidative stress-induced sperm DNA fragmentation or chronic stress-mediated reproductive suppression.

Botanical aphrodisiacs effectively complement synthetic drugs by providing broad antioxidant protection, adaptogenic stress mitigation, and cellular support for spermatogenesis. A structured integrative framework—combining targeted synthetic pharmaceuticals for acute mechanical or endocrine deficits with standardized botanical supplements for cellular protection—presents a highly promising strategy for optimizing clinical pregnancy rates [29].

## 8. Conclusion

Both synthetic and natural aphrodisiacs fulfill crucial roles in the comprehensive management of sexual dysfunction and infertility. Standard pharmaceuticals like Sildenafil citrate, Tadalafil, Clomiphene, and Cabergoline remain primary choices for acute vascular and endocrine interventions. Concurrently, botanical remedies including *Tribulus terrestris*, *Panax ginseng*, *Maca*, and *Withania somnifera* provide broad cellular protection, stress reduction, and gonadal support. Rigorous clinical validation and standardized integrative protocols remain necessary to maximize therapeutic efficacy while guaranteeing patient safety.

**References**


1. World Health Organization (WHO). (2021). *WHO Laboratory Manual for the Examination and Processing of Human Semen* (6th ed.). World Health Organization.

2. Agarwal, A., Mulgund, A., Hamada, A., & Chyette, M. R. (2015). A unique view on male infertility around the globe. *Reproductive Biology and Endocrinology*, 13(1), 37.

3. Corbin, J. D. (2004). Mechanisms of action of PDE5 inhibitors in erectile dysfunction. *International Journal of Impotence Research*, 16(1), S4-S7.

4. Tomar, A., & Singh, R. (2020). Ethnomedicinal plants used as aphrodisiacs in traditional systems of medicine: A review. *Journal of Ethnopharmacology*, 250, 112485.

5. Melis, M. R., & Argiolas, A. (1995). Dopamine and central control of sexual behavior: From past to the present. *Progress in Neurobiology*, 45(1), 1-43.

6. Ignarro, L. J., Byrns, R. E., Buga, G. M., & Wood, K. S. (1987). Endothelium-derived relaxing factor from active human and rabbit blood vessels is nitric oxide. *Proceedings of the National Academy of Sciences*, 84(24), 9265-9269.

7. Tenover, J. S., & Matsumoto, A. M. (1988). Clomiphene citrate therapy in chronic male infertility. *Fertility and Sterility*, 49(6), 1042-1048.

8. Goldstein, I., Lue, T. F., Padma-Nathan, H., et al. (1998). Oral sildenafil in the treatment of erectile dysfunction. *New England Journal of Medicine*, 338(20), 1397-1404.

9. Sher, G., & Fisch, J. D. (2002). Vaginal sildenafil citrate improves endometrial thickness and clinical pregnancy rates in cases of previous implantation failure. *Fertility and Sterility*, 78(5), 1073-1076.

10. Webb, D. J., Freestone, S., Allen, M. J., & Muirhead, G. J. (1999). Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and an alpha-blocker. *The American Journal of Cardiology*, 83(5), 21-28.

11. Ring, J. D., Lwin, L. T., & Köhler, T. S. (2016). Current review of testosterone deficiency and recovery using selective estrogen receptor modulators. *Current Urology Reports*, 17(5), 38.

12. Colao, A., Sarno, K., Landi, M. L., et al. (1997). Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. *The Journal of Clinical Endocrinology & Metabolism*, 82(11), 3574-3579.

13. De Rosa, M., Colao, A., Di Sarno, A., et al. (1998). Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males. *European Journal of Endocrinology*, 138(3), 286-293.

14. Clayton, A. H., Althof, S. E., Kingsberg, S., et al. (2019). Bremelanotide for female hypoactive sexual desire disorder: randomized studies. *Obstetrics & Gynecology*, 134(4), 715-725.

15. Gauthaman, K., & Adaikan, P. G. (2008). The hormonal effects of *Tribulus terrestris* and its role in the management of male erectile dysfunction. *Phytomedicine*, 15(1-2), 44-54.

16. Roaiah, M. F., El Khayat, Y. I., Ammar, S. M., & Kamal, S. M. (2016). Pilot study on the effect of botanical medicine in treating oligospermia. *International Journal of Fertility & Sterility*, 10(2), 108-114.

17. De Andrade, E., de Azevedo, A. C., Washington, L., et al. (2007). Nitric oxide-dependent relaxation of corpus cavernosum and rabbit aorta by *Panax ginseng*. *Asian Journal of Andrology*, 9(2), 241-248.

18. Murphy, L. L., & Lee, T. J. (2002). Ginseng, sex, and the endothelium. *Annals of the New York Academy of Sciences*, 962(1), 372-381.

19. Gonzales, G. F. (2012). Ethnobiology and ethnopharmacology of *Lepidium meyenii* (Maca). *Evidence-Based Complementary and Alternative Medicine*, 2012, 193496.

20. Gonzales, G. F., Cordova, A., Vega, K., et al. (2003). Effect of *Lepidium meyenii* (Maca) on sexual desire and its absent relationship with serum testosterone. *Andrologia*, 35(6), 355-362.

21. Mahdi, A., Shukla, K. K., Ahmad, M. K., et al. (2009). Withania somnifera improves semen quality in stress-related male fertility. *Evidence-Based Complementary and Alternative Medicine*, 6(3), 325-331.

22. Ambiye, V. R., Langade, D., Dongre, S., et al. (2013). Clinical evaluation of spermatogenic activity of Ashwagandha in oligospermic males. *Evidence-Based Complementary and Alternative Medicine*, 2013, 571420.

23. Tambi, M. I., Imran, M. K., & Henkel, R. R. (2012). Standardized water-soluble extract of *Eurycoma longifolia* as testosterone booster. *Andrologia*, 44(s1), 226-230.

24. Ismail, S. B., Wan Mohammad, W. M., George, A., et al. (2012). Randomized clinical trial on *Eurycoma longifolia* for managing erectile function. *Andrologia*, 44(s1), 231-236.

25. Izzo, A. A., & Ernst, E. (2009). Interactions between herbal medicines and prescribed drugs: An updated systematic review. *Drugs*, 69(13), 1777-1798.

26. Cohen, P. A., Avula, B., & Khan, I. A. (2012). Adulteration of herbal supplements with synthetic phosphodiesterase-5 inhibitors. *JAMA Internal Medicine*, 172(5), 425-427.

27. Ernst, E. (2002). Adulteration of Chinese herbal medicines with synthetic drugs: A systematic review. *The Medical Journal of Australia*, 176(12), 603-605.

28. Sandhu, J. S., Shah, N., Tanwar, S. D., et al. (2010). An efficacy study of *Tribulus terrestris* on male sexual function. *Asian Journal of Andrology*, 12(6), 720-724.

29. Agarwal, A., & Said, T. M. (2005). Oxidative stress, DNA damage and apoptosis in male infertility: A clinical approach. *BJU International*, 95(4), 503-507.